Dr. Agarwal on Androgen Receptor Inhibitors for Prostate Cancer
Neeraj Agarwal, MD
Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses androgen receptor (AR) inhibitors for patients with prostate cancer.
Several AR inhibitors are being tested in the first-line setting, such as apalutamide, explains Agarwal. In the next 2 or 3 years, there will be multiple new AR inhibitors with their own benefits and adverse events.
According to Agarwal, it will be challenging for community oncologists to determine the ideal choice for patients with prostate cancer.